MedTrace Logo

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

NCT05822609 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-08-28

No results posted yet for this study

Summary

The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.

Conditions

Interventions

DRUG

Semaglutide

1.0 mg

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Juvenile Diabetes Research Foundation

    collaborator OTHER

  • University of Colorado, Denver

    collaborator OTHER

  • Providence Healthcare

    collaborator OTHER

  • University of Toronto

    collaborator OTHER

  • University of Washington

    lead OTHER

Principal Investigators

  • Ian de Boer, MD, MS · University of Washington

  • Jessica Kendrick, MD · University of Colorado Anschutz Medical Campus and Children's Hospital Colorado

  • David Cherney, PhD, MD · University of Toronto

  • Irl Hirsch, MD · University of Washington

  • Katherine Tuttle, MD · Providence Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-05
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05822609 on ClinicalTrials.gov